Amalgamated Bank Zentalis Pharmaceuticals, Inc. Transaction History

Amalgamated Bank

$12.2 Billion
Q4 2024

A detailed history of Amalgamated Bank transactions in Zentalis Pharmaceuticals, Inc. stock. As of the latest transaction made, Amalgamated Bank holds 1,987 shares of ZNTL stock, worth $4,828. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,987

Previous 1,987 -0.0%

Holding current value

$4,828

Previous $7,000 14.29%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 23, 2024	SELL	$10.83 - $16.49 $68,326 - $104,035	-6,309 Reduced 76.05%	1,987 $31,000
Q4 2023 Feb 06, 2024	SELL	$9.84 - $20.13 $1,849 - $3,784	-188 Reduced 2.22%	8,296 $126,000
Q3 2023 Nov 08, 2023	BUY	$19.63 - $28.29 $19,845 - $28,601	1,011 Added 13.53%	8,484 $170,000
Q2 2023 Aug 11, 2023	BUY	$17.41 - $30.05 $16,487 - $28,457	947 Added 14.51%	7,473 $210,000
Q1 2023 May 02, 2023	SELL	$16.14 - $24.94 $15,413 - $23,817	-955 Reduced 12.77%	6,526 $112,000
Q3 2022 Nov 09, 2022	BUY	$20.23 - $31.73 $29,434 - $46,167	1,455 Added 24.15%	7,481 $162,000
Q2 2022 Aug 15, 2022	BUY	$17.91 - $52.25 $1,450 - $4,232	81 Added 1.36%	6,026 $169,000
Q1 2022 Jun 30, 2022	SELL	$41.58 - $80.89 $18,378 - $35,753	-442 Reduced 6.92%	5,945 $274,000
Q4 2021 Feb 15, 2022	BUY	$66.92 - $84.79 $401 - $508	6 Added 0.09%	6,387 $537,000
Q3 2021 Oct 29, 2021	BUY	$46.83 - $73.5 $4,823 - $7,570	103 Added 1.64%	6,381 $425,000
Q2 2021 Aug 16, 2021	BUY	$37.41 - $62.25 $234,859 - $390,805	6,278 New	6,278 $334,000
Q1 2021 May 13, 2021	SELL	$35.69 - $52.72 $148,042 - $218,682	-4,148 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$31.71 - $57.97 $131,533 - $240,459	4,148 New	4,148 $215,000

Others Institutions Holding ZNTL

# of Institutions

148

Shares Held

64M

Call Options Held

55.5K

Put Options Held

71.4K

View Full List

About Zentalis Pharmaceuticals, Inc.

Ticker ZNTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,983,600
Market Cap $138M
Description
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...

More about ZNTL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Amalgamated Bank, based on Form 13F filings with the SEC.

News

Stay updated on Amalgamated Bank with notifications on news.

Account

Amalgamated Bank Zentalis Pharmaceuticals, Inc. Transaction History